Mostrando 7 resultados de: 7
Filtros aplicados
Publisher
Biomedicine and Pharmacotherapy(2)
Frontiers in Aging Neuroscience(1)
Journal of Controlled Release(1)
Journal of Nanobiotechnology(1)
Neurodegenerative Disease Management(1)
Origen
scopus(7)
Benzodiazepines and Related Drugs as a Risk Factor in Alzheimer's Disease Dementia
ArticleAbstract: Benzodiazepines (BZDs) and Z-drugs are compounds widely prescribed in medical practice due to theirPalabras claves:Alzheimer's disease, benzodiazepines, COGNITION, dementia, RISK FACTORSAutores:Antoni Camins, Auladell C., Bulló M., Busquets O., Cano A., Castro-Torres R.D., Ettcheto M., Folch J., García M.L., Manzine P.R., Olloquequi J., Sanchez-Lopez E., Zárate C.B.Fuentes:scopusA metabolic perspective of late onset Alzheimer's disease
ReviewAbstract: After decades of research, the molecular neuropathology of Alzheimer's disease (AD)is still one of tPalabras claves:Alzheimer's disease, c-Jun N-terminal kinase inhibitors, Insulin, Licochalcone A, neuroinflammation, Reticulum stress, Type 2 Diabetes mellitusAutores:Antoni Camins, Auladell C., Busquets O., Cano A., Castro-Torres R.D., Ettcheto M., Folch J., García M.L., Manzine P.R., Olloquequi J., Sanchez-Lopez E., Verdaguer E., Zárate C.B.Fuentes:scopusADAM10 in Alzheimer's disease: Pharmacological modulation by natural compounds and its role as a peripheral marker
ReviewAbstract: Alzheimer's disease (AD) represents a global burden in the economics of healthcare systems. Amyloid-Palabras claves:ADAM10, Alzheimer's disease, Natural compounds, Pharmaceutical, α-SecretaseAutores:Antoni Camins, Busquets O., Cano A., Cominetti M.R., Di Luca M., Endres K., Ettcheto M., Manzine P.R., Marcello E., Olloquequi J., Pelucchi S.Fuentes:scopusDual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)/Ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe/PS1dE9 Alzheimer's disease mice model
ArticleAbstract: Epigallocatechin-3-gallate (EGCG) is a candidate for treatment of Alzheimer's disease (AD) but its iPalabras claves:Alzheimer's disease, APP/PS1 mice, EGCG, Epigallocatechin gallate, PLGA-PEG, Polymeric nanoparticlesAutores:Antoni Camins, Auladell C., Barenys M., Barroso E., Cano A., Chang J.H., Espina M., Ettcheto M., Folch J., García M.L., Kühne B.A., Souto E.M.B., Turowski P.Fuentes:scopusMasitinib for the treatment of alzheimer's disease
ArticleAbstract: The actual standard treatment for mild-to-moderately severe Alzheimer's disease only attacks its symPalabras claves:Alzheimer's disease, clinical trials, masitinib, mechanism of actionAutores:Antoni Camins, Auladell C., Cano A., Ettcheto M., Folch J., Sanchez-Lopez E., Verdaguer E.Fuentes:scopusMemantine loaded PLGA PEGylated nanoparticles for Alzheimer's disease: In vitro and in vivo characterization
ArticleAbstract: Background: Memantine, drug approved for moderate to severe Alzheimer's disease, has not shown to bePalabras claves:Alzheimer's disease, APPswe/PS1dE9 mice, astrocytes, BEnd.3, Brain targeting, Memantine, Nanoparticles, β-Amyloid plaquesAutores:Antoni Camins, Calpena A.C., Cano A., Carmona N., Egea M.A., Espina M., Ettcheto M., García M.L., Sanchez-Lopez E., Silva A.M., Souto E.M.B.Fuentes:scopusProtein tyrosine phosphatase 1B (PTP1B) as a potential therapeutic target for neurological disorders
ReviewAbstract: Protein tyrosine phosphatase 1B (PTP1B) is a typical member of the PTP family, considered a direct nPalabras claves:Alzheimer's disease, insulin receptor, neurodegenerative diseases, neuroinflammation, Neurological disorders, PTP1B, Type 2 DiabetesAutores:Antoni Camins, Auladell C., Bulló M., Cano A., Carrasco M., Ettcheto M., Folch J., Fortuna A., Olloquequi J., Sanchez-Lopez E., Verdaguer E.Fuentes:scopus